Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Several other research firms have also issued reports on CTSO. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Monday, January 13th. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Down 1.0 %

Shares of CTSO opened at $1.03 on Tuesday. The firm has a market cap of $56.32 million, a P/E ratio of -2.86 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.59. The stock has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $1.04.

Institutional Trading of Cytosorbents

Several large investors have recently modified their holdings of CTSO. Atomi Financial Group Inc. purchased a new stake in Cytosorbents in the 3rd quarter worth approximately $51,000. Geode Capital Management LLC boosted its stake in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Sargent Investment Group LLC raised its stake in Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after buying an additional 192,747 shares in the last quarter. 32.87% of the stock is owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.